TABLE 3.
Characteristics | No. Patients | Overall Survival | |
---|---|---|---|
HR (95% CI) | P | ||
Sex | |||
Female (reference) | 34 | 1.00 | |
Male | 50 | 1.35 (0.78–2.34) | 0.28 |
Age | 84 | 1.02 (0.99–1.06) | 0.15 |
Tumor differentiation | |||
Well-moderate (reference) | 58 | 1.00 | |
Poor | 26 | 1.16 (0.64–2.12) | 0.63 |
pT stage (AJCC 8th edition) | 0.09 | ||
pT1 (reference) | 12 | 1.00 | |
pT2 | 61 | 2.89 (1.13–7.42) | 0.03 |
pT3 | 11 | 2.46 (0.77–7.86) | 0.13 |
pN stage (AJCC 8th edition) | 0.02 | ||
pN0 (reference) | 16 | 1.00 | |
pN1 | 32 | 2.47 (0.93–6.55) | 0.07 |
pN2 | 36 | 3.85 (1.45–10.19) | 0.007 |
Margin | |||
Negative (reference) | 75 | 1.00 | |
Positive | 9 | 5.29 (2.26–12.4) | <0.001 |
PERK expression | |||
Low (reference) | 42 | 1.00 | |
High | 42 | 1.77 (1.00–3.12) | 0.05 |
p-eIF2α Expression | |||
Low (reference) | 37 | 1.00 | |
High | 47 | 1.94 (1.08–3.50) | 0.03 |